halopemide

Names

[ Name ]:
halopemide

[Synonym ]:
halopemide ( N-<2-<4-(5-chloro-2-oxo-1-benzimidazolinyl)piperidino>ethyl>-p-fluorobenzamide )
Halopemidum
Halopemida
N-{2-[4-(5-Chloro-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl}-4-fluorobenzamide
N-(2-(4-(5-Chloro-2-oxo-1-benzimidazolinyl)piperidino)ethyl)-p-fluorobenzamide
5-chloro-1-{1-[2-(4-fluoro-benzoylamino)-ethyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one
N-2-[4-(5-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl-4-fluoro benzamide
N-{2-[4-(5-Chloro-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl]ethyl}-4-fluorobenzamide
R 34,301
Benzamide, N-[2-[4-(5-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-4-fluoro-
halopemide
Halopemide (USAN/INN)
N-[2-[4-(5-Chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-4-fluorobenzamide

Biological Activity

[Description]:

Halopemide is a potent phospholipase D (PLD) inhibitor, with IC50s of 220 and 310 nM for human PLD1 and PLD2, respectively. Halopemid is a dopamine receptors antagonist, and acts a psychotropic agent[1][2].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Metabolic Enzyme/Protease >> Phospholipase

Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor

Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor

Research Areas >> Neurological Disease

[Target]

PLD1:220 nM (IC50)

PLD2:310 nM (IC50)

dopamine receptors

[In Vitro]

Halopemide (1-2 μM; 21 day) affects calcification in transdifferentiated MOVAS cells[3].

[In Vivo]

Halopemide (10 mg/kg; p.o.) induces dyskinesias in the majority of monkeys tested[2].

[References]

[1]. Scott SA, et al. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol. 2009 Feb;5(2):108-17.

[2]. Neale R, et al. Acute dyskinesias in monkeys elicited by halopemide, mezilamine and the "antidyskinetic" drugs, oxiperomide and tiapride. Psychopharmacology (Berl). 1981;75(3):254-7.

[3]. Skafi N, et al. Phospholipase D: A new mediator during high phosphate-induced vascular calcification associated with chronic kidney disease. J Cell Physiol. 2019 Apr;234(4):4825-4839.

Chemical & Physical Properties

[ Density]:
1.3±0.1 g/cm3

[ Molecular Formula ]:
C₂₁H₂₂ClFN₄O₂

[ Molecular Weight ]:
416.876

[ Exact Mass ]:
416.141541

[ PSA ]:
70.13000

[ LogP ]:
4.47

[ Index of Refraction ]:
1.612

[ Storage condition ]:
2-8°C

MSDS

Click to get detail MSDS

Safety Information

[ Symbol ]:

GHS07

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H302

[ Hazard Codes ]:
Xn

[ RIDADR ]:
NONH for all modes of transport

Articles

CAY10593 inhibits the human P2X7 receptor independently of phospholipase D1 stimulation.

Purinergic Signal. 9(4) , 609-19, (2013)

The P2X7 receptor is a trimeric ATP-gated cation channel important in health and disease. We have observed that the specific phospholipase D (PLD)1 antagonist, CAY10593 impairs P2X7-induced shedding o...

Halopemide, a new psychotropic agent. Cerebral distribution and receptor interactions.

Pharm. Weekbl. Sci. 7(1) , 1-9, (1985)

Halopemide is a new psychotropic agent, a structural analogue of the neuroleptics of the butyrophenone type but with different pharmacological and clinical properties. Preliminary clinical findings in...

Dynamic cation-exchange systems for the separation of drugs derived from butyrophenone and diphenylpiperidine by high-performance liquid chromatography and applied in the determination of halopemide in plasma.

J. Chromatogr. A. 164(2) , 177-85, (1979)

Dynamic (solvent generated) cation-exchange systems for the separation of drugs and main metabolites derived from butyrophenone and diphenylpiperidine (haloperidol, pimozide, halopemide) were investig...

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.